Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $40.78, for a total value of $815,600.00. Following the completion of the transaction, the executive vice president directly owned 60,000 shares of the company’s stock, valued at approximately $2,446,800. This trade represents a 25.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Marshall Urist also recently made the following trade(s):

• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded up $0.10 during trading on Tuesday, hitting $40.36. 4,907,357 shares of the company’s stock traded hands, compared to its average volume of 3,801,906. The company has a market cap of $23.30 billion, a PE ratio of 30.58, a PEG ratio of 1.93 and a beta of 0.43. The firm’s fifty day moving average price is $39.24 and its 200 day moving average price is $37.33. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $41.70. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. The firm had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. Analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 annualized dividend and a yield of 2.3%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s payout ratio is presently 66.67%.

Analyst Ratings Changes

A number of brokerages have issued reports on RPRX. The Goldman Sachs Group assumed coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective for the company. TD Cowen lifted their price target on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Finally, Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.60.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in RPRX. Nordea Investment Management AB lifted its stake in Royalty Pharma by 603.9% in the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock valued at $23,701,000 after acquiring an additional 562,799 shares in the last quarter. Watchtower Advisors LP acquired a new stake in shares of Royalty Pharma in the second quarter valued at approximately $3,603,000. World Investment Advisors bought a new stake in shares of Royalty Pharma in the third quarter worth $1,702,000. Financiere des Professionnels Fonds d investissement inc. acquired a new position in Royalty Pharma during the third quarter worth $933,000. Finally, Generali Asset Management SPA SGR boosted its holdings in Royalty Pharma by 7,752.8% during the third quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock worth $1,202,000 after purchasing an additional 33,647 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.